<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The protective effects of <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> and d,l-lysine <z:chebi fb="0" ids="13719">acetylsalicylate</z:chebi> (L-<z:chebi fb="37" ids="15365">ASA</z:chebi>), used alone and in combination, on the pathogenesis of <z:mp ids='MP_0005048'>thrombosis</z:mp> in cerebral blood vessels were investigated in a rat animal model using a He-Ne laser method </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="9588">Ticlopidine</z:chebi> and L-<z:chebi fb="37" ids="15365">ASA</z:chebi>, given orally at a concentration from 100 mg/kg, inhibited <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in a dose-dependent manner </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="9588">Ticlopidine</z:chebi> (300 mg/kg p.o.) inhibited <z:mp ids='MP_0005048'>thrombosis</z:mp> in arterioles and venules for 3 days after administration </plain></SENT>
<SENT sid="3" pm="."><plain>The inhibitory activity of L-<z:chebi fb="37" ids="15365">ASA</z:chebi> (300 mg/kg p.o.) was less prolonged than that of <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> and was observed for only approximately 24 h </plain></SENT>
<SENT sid="4" pm="."><plain>Combined administration of <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> and L-<z:chebi fb="37" ids="15365">ASA</z:chebi> significantly enhanced and prolonged the antithrombotic effects of either drug given alone </plain></SENT>
<SENT sid="5" pm="."><plain>The results demonstrate that <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> and L-<z:chebi fb="37" ids="15365">ASA</z:chebi> have potent antithrombotic properties in rat cerebral blood vessels in vivo </plain></SENT>
</text></document>